Drug Trial Radar · NCT06483555
Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel
Last checked: Nov 19, 2026Latest source record: Apr 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
104
Planned (sponsor's estimate)
Start
Feb 6, 2025
Primary completion
Aug 2027
Study completion Aug 2027
Sponsor
- Lead sponsor
- UNC Lineberger Comprehensive Cancer CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jul 3, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase I/II clinical trial is being conducted at multiple centers to find out whether adding a low dose of EGFR blocking drugs to the standard chemotherapy combination of gemcitabine and nab paclitaxel (GnP) is safe, tolerable, and helpful for people with advanced pancreatic cancer. All participants are first tested with a tool called PurIST, which classifies tumors as either "basal-like" or "classical." People with basal-like tumors will receive GnP plus erlotinib during Phase I so researchers can determine the safest and most effective dose. Once that dose is identified, the study moves to Phase II, where people with basal-like tumors will be randomly assigned to receive either GnP alone or GnP with erlotinib. Phase II may also test new drug combinations if new treatments become approved during the study period. Overall, the trial plans to include up to about 52 basal-like patients in Phase I, roughly 82 basal-like patients in Phase II, and at least 52 classical patients, with the possibility of enrolling more if needed. People whose tumors are classified as classical will continue with standard treatments recommended by their doctors or other clinical trials. Across the entire study, researchers will carefully track long-term outcomes such as overall survival, how long patients live before the cancer progresses, and how well their tumors respond to treatment.
Conditions
- Pancreatic Adenocarcinoma
- Metastatic Pancreatic Cancer
- Basal Cell Neoplasm
Interventions
GemcitabineDrug
1000 mg/m2, intravenously on day 1 and day 15, for subjects with basal-like cell type pancreatic carcinoma.
Nab paclitaxelDrug
125 mg/m2 intravenously on day 1 and day 15 for subjects with basal-like cell type pancreatic carcinoma.
ErlotinibDrug
50 mg per oral daily. for subjects with basal-like cell type pancreatic carcinoma.
NALIRIFOXDrug
Subjects with classical pancreatic adenocarcinoma will receive. NALIRIFOX is liposomal irinotecan with 5-fluorouracil/leucovorin and oxaliplatin. Dosing and plan will be decided by the treating physician.
FolfirinoxDrug
Subjects with classical pancreatic adenocarcinoma will receive. Dosing and plan will be decided by the treating physician.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse Events per Common Terminology Criteria for Adverse Events (NCI-CTCAE)Time frame: First day of study treatment through the 28 days after last treatment
- Dose-limiting toxicity (DLT)Time frame: Up to 28 days
- Overall survival- classical metastatic pancreatic adenocarcinomaTime frame: 2 years
- Progression-free survivalTime frame: 2 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.